VIFOR INTERNATIONAL AG

India's Supreme Court to Determine Competition Commission's Authority Over Patent-Related Antitrust Cases

- India's Supreme Court will rule on whether the Competition Commission of India (CCI) has jurisdiction to investigate anti-competitive conduct arising from patent rights exercise, following conflicting tribunal decisions. - The case centers on pharmaceutical company Vifor International AG's patented drug Ferric Carboxymaltose (FCM), where the National Company Law Appellate Tribunal ruled the CCI lacks jurisdiction over patent-related competition disputes. - The Supreme Court has stayed portions of the NCLAT ruling that held the Patents Act, 1970 overrides the Competition Act, 2002 in matters involving patent rights abuse. - The decision will significantly impact pharmaceutical and technology companies' patent strategies and market operations in India, particularly regarding licensing practices and competition law compliance.